KYMR
Kymera Therapeutics, Inc.84.19
-1.49-1.74%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
6.74BP/E (TTM)
-Basic EPS (TTM)
-3.60Dividend Yield
0%Recent Filings
8-K
Kymera prices $602M offering
Kymera Therapeutics priced its upsized follow-on offering of 7M shares at $86 each on December 9, 2025, with underwriters exercising the full 1.05M option; net proceeds hit $656.1M. Funds will fuel pipeline advancement for degraders targeting immunology diseases and general corporate needs. Cash runway extends into 2029. Closing set for December 11, pending conditions.
8-K
KT-621 Phase 1b AD data shines
Kymera unveiled positive BroADen Phase 1b results for KT-621 on December 8, 2025, showing 94% median STAT6 degradation in skin, 63% mean EASI reduction, and 40% peak pruritus drop across 22 moderate-to-severe AD patients after 28 days of 100-200mg dosing. Well-tolerated with no serious AEs, it matched or beat dupilumab benchmarks while hitting comorbid asthma signals. Phase 2b trials advance in AD and asthma. Cross-trial comparisons unreliable.
8-K
KT-621 Phase 1b AD data shines
Kymera unveiled positive Phase 1b BroADen results for oral STAT6 degrader KT-621 in moderate-to-severe atopic dermatitis patients on December 8, 2025. Daily doses of 100-200mg drove 98% blood and 94% skin STAT6 degradation, 63% mean EASI reduction, 74% TARC drop, and robust pruritus relief—matching or exceeding dupilumab's week-4 data. Well-tolerated. Phase 2b asthma trial starts Q1 2026.
8-K
CLO retires; Adams appointed
Kymera Therapeutics' Chief Legal Officer Ellen Chiniara retires effective September 3, 2025, with no disagreements or severance. Brian Adams, J.D., with nearly two decades in life sciences leadership from Relay Therapeutics and others, succeeds her immediately. Smooth transition bolsters legal expertise amid clinical scaling.
8-K
KT-621 Phase 1 beats targets
Kymera Therapeutics reported Q2 2025 results, highlighting positive Phase 1 data for KT-621 STAT6 degrader that exceeded targets with >90% degradation and dupilumab-like Th2 biomarker cuts, yet safe as placebo. BroADen Phase 1b AD data due 4Q25; Phase 2b trials start 4Q25/1Q26. Struck Gilead CDK2 deal for up to $750M; $1B cash funds runway to H2 2028. Net loss widened to $76.6M on R&D ramp.
IMA
ImageneBio, Inc.
6.25+0.08
IMRX
Immuneering Corporation
5.74-0.04
KPRX
Kiora Pharmaceuticals, Inc.
2.04-0.02
KYTX
Kyverna Therapeutics, Inc.
10.24-0.58
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
NKTR
Nektar Therapeutics
49.16-4.14
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
VYNE
VYNE Therapeutics Inc.
0.40+0.04
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00